Renata PLC (DSE:RENATA)

Market Cap	53.99B -25.7%
Revenue (ttm)	44.26B +10.9%
Net Income	2.54B -14.2%
EPS	22.11 -14.2%
Shares Out	114.70M
PE Ratio	21.29
Forward PE	15.85
Dividend	5.50 (1.17%)
Ex-Dividend Date	Nov 18, 2025

Volume	75,995
Average Volume	55,354
Open	458.70
Previous Close	457.40
Day's Range	457.50 - 472.50
52-Week Range	372.00 - 548.00
Beta	-0.09
RSI	76.98
Earnings Date	Jan 29, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia...

• Industry: Pharmaceutical Preparations
• Founded: 1972
• Employees: 8,366
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: RENATA

Financial Performance

In fiscal year 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.